Ann: Appendix 4C - quarterly, page-34

FFS, operating cash flows does not include financing casflows. Inflows from Orbimed and Discovery are financing casflows, not receipts.

My 2c, the operating inflows are made up of $15m from Amgen (which means we received that payment in Dec), $1.2m from Abbvie and the balance from PFS and Medimmune WIs. I reckon payment for those WIs will span over Dec and March qtrs